Research programme: cancer therapeutics - Immunome

Drug Profile

Research programme: cancer therapeutics - Immunome

Alternative Names: IMM 002; IMM 003; IMM 005; IMM 009; IMM 010; IMM 039

Latest Information Update: 05 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunome
  • Class CAR-T cell therapies; Gene therapies; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer
  • Research Colorectal cancer; Solid tumours
  • Discontinued Unspecified

Most Recent Events

  • 30 Dec 2015 Immunome and the unknown biotechnology company enter into a collaboration agreement to identify and validate targets for Cancer therapeutics
  • 21 Dec 2015 Discontinued for Undefined indication in USA (Parenteral)
  • 21 Dec 2015 Early research in Colorectal cancer and Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top